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Abstract
Background: To analyze the impact of weight loss before and during chemoradiation on survival outcomes in patients
with locally advanced head and neck cancer.
Methods: From 07/1994-07/2000 a total of 224 patients with squamous cell carcinoma of the head and neck
were randomized to either hyperfractionated radiation therapy alone or the same radiation therapy combined
with two cycles of concomitant cisplatin. The primary endpoint was time to any treatment failure (TTF); secondary
endpoints were locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS) and overall survival
(OS). Patient weight was measured 6 months before treatment, at treatment start and treatment end.
Results: The proportion of patients with >5% weight loss was 32% before, and 51% during treatment, and the
proportion of patients with >10% weight loss was 12% before, and 17% during treatment. After a median follow-up of
9.5 years (range, 0.1 – 15.4 years) weight loss before treatment was associated with decreased TTF, LRRFS, DMFS, cancer
specific survival and OS in a multivariable analysis. However, weight loss during treatment was not associated
with survival outcomes.
Conclusions: Weight loss before and during chemoradiation was commonly observed. Weight loss before but not
during treatment was associated with worse survival.
Keywords: Weight loss, Chemotherapy, Cisplatin, Head and neck cancer, Hyperfractionated radiation therapy, Survival,
Malnutrition
Background
Weight loss is frequently observed in patients with head
and neck squamous cell cancer (HNSCC). Weight loss be-
fore chemoradiation has been associated with decreased
overall survival by us and others [1-3], however, weight
loss during chemoradiation was also associated with poor
cancer specific survival, overall survival and disease-free
survival in HNSCC [3-5]. Here we report detailed weight
loss data before and during chemoradiation and its
associations with survival outcomes using long-term
follow-up data from our prospective trial testing con-
comitant cisplatin and hyperfractionated radiation therapy
(RT) vs. hyperfractionated RT alone in advanced HNSCC.
Methods
Patient selection and treatment
As previously described [1], all eligible patients had invasive
HNSCC of the oral cavity, oro- or hypopharynx, or larynx.
All patients gave informed consent and a total of 224 pa-
tients were randomized between July 1994 and July 2000.
Patients were treated with 1.2 Gy RT twice daily with
an interfraction interval of at least 6 hours, 5 days per
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week, up to a median total dose of 74.4 Gy (range, 72 –
76.8 Gy). In patients of the combined arm cisplatin
20 mg/m2 was administered with intravenous hydration
on 5 consecutive days during weeks 1 and 5 or 6 of RT,
1.5 hours before the afternoon RT session.
The trial was registered at the National Institutes
of Health (www.clinicaltrials.gov; identifier number:
NCT00002654) and was approved by the ethics com-
mittees of all participating institutions.
Endpoints and statistics
Patient weight was measured 6 months before treatment
(patients were asked to recall their weight 6 months be-
fore), at treatment start, before the second cycle and at
the end of treatment. Weight loss before treatment was
defined as the weight loss from 6 months before treatment
start until treatment start. Weight loss during treatment
was defined as the maximal weight loss from treatment
start to the beginning of the second cycle and the end of
treatment. Weight loss was categorized to “no weight
loss”, “≤5% weight loss”, “>5-10% weight loss” and “>10%
weight loss” [6].
The primary endpoint was time to any treatment failure
(TTF). Secondary endpoints included time to local or re-
gional treatment failure (LRRFS), distant metastasis-free
survival (DMFS) and overall survival (OS).
All time-to-event end-points were calculated from the
date of randomization and were tested for differences using
the log-rank test. Treatment failure was defined as either
tumor recurrence at any site, salvage surgery, second pri-
mary tumor, or death of any cause which ever occurred
first. Locoregional failure was defined as local or nodal pro-
gression or recurrence or death as a result of tumor. Diag-
nosis of distant metastasis and death as a result of tumor
were considered as events in the time to distant metastasis
analysis. Uni- and multivariable Cox regressions were per-
formed to assess prognostic variables. In addition to treat-
ment arm, the following clinical and pathological variables
were considered as covariates in the regression models:
gender (female vs. male), performance status (WHO grade 0
vs. grade 1–2), primary tumor site (other sites vs. hypophar-
ynx), tumor classification (cT1-2 vs. cT3-4), nodal classifica-
tion (cN0-1 vs. cN2-3), age (<50 years vs. ≥50 years), acute
or late dysphagia (grade 0–2 vs. grade ≥ 3). Categorical
endpoints were compared using Fisher’s exact test. As
no adjustment for multiple testing was applied all analyses
were exploratory and hypothesis generating. Statistical
analyses were performed using SAS version 9.2 (SAS
Institute Inc., Cary, NC, USA).
Results
Incidence and magnitude of weight loss
Patient weight loss at different time points was summarized
in Table 1. The proportion of patients with >5% weight loss
was 32% before, and 51% during treatment, and the propor-
tion of patients with >10% weight loss was 12% before, and
17% during treatment. In the 57% of patients who did not
lose >5% weight before treatment the proportion of pa-
tients having >5% and >10% weight loss during treatment
was 67% and 44% while in the 32% of patients who had
lost >5% weight before treatment 63% and 31% lost >5%
and >10% weight, respectively. For 11% of the patients the
weight loss before treatment could not be assessed. A total
of 6 patients (3%) underwent parenteral nutrition and 72
patients (32%) received a feeding tube.
Clinical predictors of weight loss
Weight loss before treatment was associated with
age <50 years (p = 0.006), WHO performance score above
0 (p = 0.004), lower baseline hemoglobin values (p < 0.001),
primary tumor site other than hypopharynx (p = 0.04) but
not with the baseline total white blood count (p = 0.5).
There was a trend between advanced T classification (p =
0.06), N classification (p = 0.07) and male gender (p = 0.09)
and increased weight loss before treatment, respectively
(Table 2). Weight loss during treatment was associated
with treatment arm B (RT alone; p = 0.05) but not with
any tested clinical variable including acute dysphagia
(Table 3).
Weight loss and survival outcomes
Median follow-up was 9.5 years (range, 0.1 – 15.4 years).
Weight loss before treatment was associated with de-
creased TTF, LRRFS, DMFS, cancer specific survival (CSS)
as well as with decreased OS (Table 4, Figures 1 and 2).
After multivariable Cox regression weight loss >10% be-
fore treatment remained associated with decreased TTF
(hazard ratio [HR], 2.8 [95% confidence interval {CI}, 1.7–
4.5; p < 0.0001]), LRRFS (2.5, [95% CI, 1.4–4.5; p = 0.002]),
Table 1 Incidence and magnitude of weight loss
Total (N = 224)
Variable n (%)
Weight loss before treatment start
No weight loss 78 (34.8%)
<=5% weight loss 49 (21.9%)
>5-10% weight loss 45 (20.1%)
>10% weight loss 27 (12.1%)
Missing 25 (11.2%)
Weight loss during treatment
No weight loss 34 (15.2%)
<=5% weight loss 73 (32.6%)
>5-10% weight loss 75 (33.5%)
>10% weight loss 39 (17.4%)
Missing 3 (1.3%)
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Table 2 Clinical predictors for weight loss before treatment
Weight loss before treatment
No weight loss <=5% weight loss >5-10% weight loss >10% weight loss p-value*
Sex = Female 15 (46.9%) 4 (12.5%) 11 (34.4%) 2 (6.2%) 0.09
Sex = Male 63 (37.7%) 45 (26.9%) 34 (20.4%) 25 (15.0%)
WHO performance = 0 51 (44.3%) 33 (28.7%) 23 (20.0%) 8 (7.0%) 0.004
WHO performance > = 1 27 (32.1%) 16 (19.0%) 22 (26.2%) 19 (22.6%)
Age < 50 years 21 (38.2%) 14 (25.5%) 6 (10.9%) 14 (25.5%) 0.006
Age > = 50 years 57 (39.6%) 35 (24.3%) 39 (27.1%) 13 (9.0%)
Site = Hypopharynx 21 (42.9%) 10 (20.4%) 16 (32.7%) 2 (4.1%) 0.04
Site = Other 57 (38.0%) 39 (26.0%) 29 (19.3%) 25 (16.7%)
T classification = cT1-2 21 (52.5%) 9 (22.5%) 9 (22.5%) 1 (2.5%) 0.06
T classification = cT3-4 57 (35.8%) 40 (25.2%) 36 (22.6%) 26 (16.4%)
N classification = cN0-1 41 (50.0%) 18 (22.0%) 15 (18.3%) 8 (9.8%) 0.07
N classification = cN2-3 37 (31.6%) 31 (26.5%) 30 (25.6%) 19 (16.2%)
Parenteral nutrition or feeding tube = No 48 (39.0%) 35 (28.5%) 22 (17.9%) 18 (14.6%) 0.2
Parenteral nutrition or feeding tube = Yes 30 (40.5%) 14 (18.9%) 22 (29.7%) 8 (10.8%)
Hemoglobin > = 14 g/dL 52 (48.1%) 30 (27.8%) 21 (19.4%) 5 (4.6%) <0.001
Hemoglobin < 14 g/dL 26 (28.6%) 19 (20.9%) 24 (26.4%) 22 (24.2%)
*Fisher‘s Exact test.
Table 3 Clinical predictors for weight loss during treatment
Weight loss during treatment
No weight loss <=5% weight loss >5-10% weight loss >10% weight loss p-value*
Sex = Female 7 (21.2%) 8 (24.2%) 13 (39.4%) 5 (15.2%) 0.5
Sex = Male 27 (14.4%) 65 (34.6%) 62 (33.0%) 34 (18.1%)
WHO performance = 0 17 (13.7%) 36 (29.0%) 43 (34.7%) 28 (22.6%) 0.1
WHO performance > = 1 17 (17.5%) 37 (38.1%) 32 (33.0%) 11 (11.3%)
Age < 50 years 13 (21.3%) 21 (34.4%) 18 (29.5%) 9 (14.8%) 0.4
Age > = 50 years 21 (13.1%) 52 (32.5%) 57 (35.6%) 30 (18.8%)
Site = Hypopharynx 10 (18.5%) 17 (31.5%) 15 (27.8%) 12 (22.2%) 0.5
Site = Other 24 (14.4%) 56 (33.5%) 60 (35.9%) 27 (16.2%)
T classification = cT1-2 4 (10.0%) 14 (35.0%) 15 (37.5%) 7 (17.5%) 0.8
T classification = cT3-4 30 (16.6%) 59 (32.6%) 60 (33.1%) 32 (17.7%)
N classification = cN0-1 14 (15.1%) 30 (32.3%) 38 (40.9%) 11 (11.8%) 0.1
N classification = cN2-3 20 (15.6%) 43 (33.6%) 37 (28.9%) 28 (21.9%)
Acute dysphagia = No 16 (16.7%) 38 (39.6%) 27 (28.1%) 15 (15.6%) 0.2
Acute dysphagia = Yes 18 (14.5%) 35 (28.2%) 47 (37.9%) 24 (19.4%)
Parenteral nutrition or feeding tube = No 24 (16.7%) 51 (35.4%) 44 (30.6%) 25 (17.4%) 0.4
Parenteral nutrition or feeding tube = Yes 9 (11.8%) 22 (28.9%) 31 (40.8%) 14 (18.4%)
Arm = A (chemoradiation) 20 (18.0%) 44 (39.6%) 30 (27.0%) 17 (15.3%) 0.05
Arm = B (radiation therapy alone) 14 (12.7%) 29 (26.4%) 45 (40.9%) 22 (20.0%)
*Fisher’s Exact test.
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DMFS (HR, 3.1 [95% CI, 1.6–6.1; p < 0.0001]), CSS (HR,
2.8 [95% CI, 1.5–5.4; p = 0.002]), and OS (HR, 3.2 [95% CI,
2.0–5.3; p < 0.0001], (Table 5)).
Weight loss during treatment, however was not associ-
ated with any of the tested survival endpoints (Table 4,
Figures 1 and 2).
Discussion
Involuntary weight loss is a major problem in patients
with locally advanced HNSCC. The reasons for weight
loss include difficulties with oral intake due to tumor-
related symptoms such as mechanical obstruction and
pain as well as treatment related toxicities. Moreover,
weight loss might also cause tumor-associated cachexia,
a condition thought to be a multifactorial metabolic dis-
order. In our trial, the proportion of patients having
weight loss >5% was 32% before, and 51% during treat-
ment, and the proportion of patients with >10% weight
loss was 12% before, and 17% during treatment. Here we
could show that weight loss >10% before treatment is a
major predicting factor of decreased survival outcomes
after chemoradiation or RT alone. In contrast and inter-
estingly, weight loss during treatment appeared not to
be associated with cancer outcome.
Obesity has previously been described to be associated
with improved OS in HNSCC and esophageal cancer [7].
For patients with locally advanced HNSCC it has been
further reported that pretreatment weight loss ≥10% was
associated with decreased OS after multivariable analysis
after chemoradiation in a retrospective analysis of a co-
hort of 92 patients [2]. In this cohort weight loss ≥10%
was observed in 49% of patients.
Langius et al. reported on 1340 prospectively collected
HNSCC patients, two thirds of those underwent primary
RT therapy or chemoradiation, the remaining patients
underwent surgery and adjuvant RT therapy. No weight
loss before treatment was observed in 70%, ≤5% in
16%, >5-10% in 9% and >10% weight loss in 5% of pa-
tients, respectively. During RT weight loss >5% was
observed in 57% of patients. Weight loss >10% before
treatment remained associated with decreased OS after
multivariable analysis and weight loss during RT remained
to be associated with decreased disease-specific-survival
after multivariable analysis [3].
In a large retrospective cohort of 1562 patients with
HNSCC in which two thirds underwent surgery and ad-
juvant RT and the remaining patients primary chemoradi-
ation Pai et al. could describe that decreased pretreatment
body mass index (BMI) was associated with decreased
CSS and OS [4]. Overall body weight loss during RT did
not influence survival outcomes (39% of patients experi-
enced a body weight loss of ≥5% during RT). In the group
with higher pretreatment BMI and less weight loss (<5%)
during treatment, however CSS, DMFS and OS was better
as compared with those patients having greater weight loss
(≥5%) during treatment.
Cho et al. reported on 226 retrospectively analyzed pa-
tients with HNSCC of which 74% underwent surgery and
61% either primary or adjuvant RT [5]. Weight loss ≥10%
during the year after initial treatment was observed in 42%
of patients. T classification and N classification were
significantly associated with the occurrence of weight
loss ≥10% in this series. After multivariable analyses,
weight loss ≥10% was a predictor of decreased disease-
free survival.
The proportion of patients observed with significant
weight loss in our trial appears to be within the range re-
ported in the literature and we could gather further indi-
cations for the importance of pretreatment weight loss as
a major prognostic factor. Interestingly, however, we could
find no indications that weight loss during treatment has
any prognostic role. This finding might question the
Table 4 Univariable Cox regression models for the influence of categorized weight loss on survival outcomes
Variable Cox regression analysis, hazard ratio (95% confidence interval) (p-value)
TTF LRRFS DMFS CSS OS
Weight loss before treatment
(<=5% vs. none)
1.5 (1.0-2.2) (0.04) 1.6 (1.0-2.6) (0.05) 1.7 (0.9-2.9) (0.09) 1.2 (0.7-2.2) (0.5) 1.4 (0.9-2.1) (0.1)
Weight loss before treatment
(>5-10% vs. none)
1.7 (1.1-2.5) (0.01) 1.4 (0.9-2.3) (0.2) 2.3 (1.3-4.0) (0.003) 2.0 (1.2-3.5) (0.01) 1.7 (1.1-2.7) (0.01)
Weight loss before treatment
(>10% vs. none)
2.7 (1.7-4.4) (<0.001) 2.6 (1.5-4.5) (<0.001) 3.1 (1.6-5.8) (<0.001) 2.8 (1.5-5.4) (0.001) 2.9 (1.8-4.8) (<0.001)
Weight loss during treatment
(<=5% vs. none)
1.1 (0.7-1.7) (0.7) 1.0 (0.6-1.8) (0.9) 1.1 (0.6-2.1) (0.7) 1.2 (0.6-2.1) (0.6) 1.2 (0.8-2.0) (0.4)
Weight loss during treatment
(>5-10% vs. none)
1.0 (0.6-1.6) (1.0) 1.0 (0.6-1.7) (0.9) 0.9 (0.5-1.7) (0.9) 1.0 (0.5-1.8) (0.9) 1.1 (0.7-1.8) (0.7)
Weight loss during treatment
(>10% vs. none)
1.1 (0.6-1.8) (0.8) 0.9 (0.5-1.7) (0.8) 0.9 (0.4-1.8) (0.7) 0.7 (0.3-1.5) (0.3) 0.9 (0.5-1.7) (0.8)
p-values for log-rank tests are displayed in the Kaplan-Meier Plots.
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benefit of a rigorous strategy against weight loss during
treatment. Taking into account both the significant mor-
bidity and costs associated with both, feeding tubes and/or
parenteral nutrition, more evidence is warranted to define
the optimal nutritional support during chemoradiation of
advanced HNSCC and its impact on treatment outcome.
We believe that pretreatment weight loss is most prob-
ably caused by cancer-associated cachexia and that it is as-
sociated with advanced disease factors and decreased
performance status. It might be that an impaired immune
response caused by significant pre-treatment weight loss
further contributes to the decreased survival outcomes.
Interestingly pretreatment weight loss was significantly as-
sociated with lower baseline hemoglobin values, a factor
which was associated with decreased survival outcomes in
a previous analysis of this dataset [1], however, baseline
hemoglobin did not remain significant in the multivariable
analysis for the different survival endpoints analyzed. One
Figure 1 Kaplan Meier plots showing patients with weight loss before and during treatment and time to any treatment failure (A,B)
locoregional failure-free survival (C,D) and distant metastasis-free survival (E,F) over 9.5 years median follow-up stratified according to
the magnitude of weight loss.
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limitation of our study is that smoking habits were not
collected as there is an association between weight, weight
loss and smoking habits and smoking status might be a
confounding factor for mortality. Another limitation of
this work is the fact that the pre-treatment weight was
asked by recall, which could potentially be associated with
some impreciseness.
In a secondary analysis of the Radiation Therapy On-
cology Group (RTOG) 90–03 trial which prospectively
collected data on nutritional support delivered before
treatment, during treatment, and after treatment data of
the 1073 evaluable patients were analyzed against outcome.
Interestingly, patients receiving pre-treatment nutritional
support experienced significantly less weight loss by the
Figure 2 Kaplan Meier plots showing patients with weight loss before and during treatment and cancer specific survival (A,B) and
overall survival (C,D) over 9.5 years median follow-up stratified according to the magnitude of weight loss.
Table 5 Multivariable Cox regression models for the influence of categorized weight loss on survival outcomes
Variable Cox regression analysis, hazard ratio (95% confidence interval) (p-value)
TTF LRRFS DMFS CSS OS
Multivariable analysis*
Treatment arm: RT only vs. combined 1.3 (1.0-1.8) (0.08) 1.6 (1.1-2.4) (0.02) 1.9 (1.2-3.0) (0.006) 1.9 (1.2-3.0) (0.006) 1.4 (1.0-2.0) (0.05)
Performance status: 1 + 2 vs. 0 1.5 (1.0-2.2) (0.06) 1.6 (1.0-2.4) (0.05) 1.8 (0.9-3.3) (0.08)
Tumor classification: cT3-4 vs. cT1-2
Nodal classification: cN2-3 vs. cN0-1 1.3 (0.9-1.8) (0.1) 1.4 (1.0-2.1) (0.08) 1.5 (1.0-2.4) (0.07) 1.5 (1.0-2.4) (0.07)
Weight loss before treatment
(<=5% vs. none)
1.4 (0.9-2.1) (0.12) 1.5 (0.9-2.5) (0.08) 1.6 (0.9-2.9) (0.1) 1.1 (0.6-1.9) (0.9) 1.3 (0.9-2.0) (0.2)
Weight loss before treatment
(>5-10% vs. none)
1.5 (1.0-2.3) (0.06) 1.2 (0.7-2.0) (0.5) 1.8 (1.0-3.2) (0.03) 1.6 (0.9-2.9) (0.08) 1.7 (1.1-2.6) (0.02)
Weight loss before treatment
(>10% vs. none)
2.8 (1.7-4.5) (<0.001) 2.5 (1.4-4.5) (0.002) 3.1 (1.6-6.1) (<0.001) 2.8 (1.5-5.4) (0.002) 3.2 (2.0-5.3) (<0.001)
*after backward selection with level 0.1.
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end of treatment and less grade 3 to 4 mucositis than pa-
tients not receiving pre-treatment nutritional support. Yet
patients receiving pre-treatment nutritional support had a
poorer 5-year actuarial locoregional control rate and a
poorer 5-year overall survival rate [8]. This finding indi-
cates that the mechanism behind the negative impact of
pretreatment weight loss is more complex than just mech-
anical obstruction and pain caused by the primary tumor.
It rather points towards biological and metabolic factors
associated with the aggressiveness of the primary tumor
and/or the tumor load. It is therefore questionable whether
the prognosis of these patients can simply be improved by
correction of the nutritional status.
Our study confirms within the frame of a prospective
randomized trial that patients with significant pretreat-
ment weight loss are at higher risk for treatment failure.
So far, no specific intervention has been established to
counteract this adverse condition in order to improve
patients’ survival. We propose to stick to a tight follow
up schedule for these high-risk patients. Moreover, as an-
other consequence of our results, we suggest that future
prospective studies in head and neck cancer might benefit
from stratification according to pretreatment weight loss.
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